Review Article

Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARs

Yuhong Yang,1 Amy E. Lovett-Racke,2 and Michael K. Racke1

1 Department of Neurology, Ohio State University Medical Center, Columbus, OH 43210, USA
2 Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center, Columbus, OH 43210, USA

Correspondence should be addressed to Yuhong Yang, yuhong.yang@osumc.edu

Received 12 June 2010; Revised 14 September 2010; Accepted 22 October 2010

Academic Editor: Béatrice Desvergne

Copyright © 2010 Yuhong Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PPARs are members of the steroid hormone nuclear receptor superfamily and play an important role in regulating inflammation as well as lipid metabolism. The PPAR subfamily has been defined as PPARα, PPARβ/δ, and PPARγ, each with different ligands, target genes, and biological roles. PPARs regulate the expression of target inflammatory genes through mechanisms involving both transactivation and transrepression. The anti-inflammatory properties of PPAR agonists have led to the investigation of PPAR functions in regulating autoimmune encephalomyelitis. This paper will summarize some of the general mechanisms by which PPARs regulate inflammatory gene expression and focus on the recent advances of PPAR regulation of autoimmune encephalomyelitis.

1. Peroxisome Proliferator-Activated Receptors (PPARs)

The nuclear receptor superfamily integrates both inflammatory and metabolic signals to maintain homeostasis in immune cells such as macrophages, dendritic cells, and lymphocytes [1, 2]. PPARs are nuclear receptors activated by fatty acids and control the expression of genes involved in both lipid metabolism and inflammation. So far, there are three isoforms that have been identified and cloned, including PPAR-α, PPAR-β/δ, and PPAR-γ, and they exhibit different tissue distribution as well as different ligand specificities. PPARα was the founding member of the PPAR subfamily and was first cloned in rodents. It was shown to be activated by a diverse class of rodent hepatocarcinogens that causes proliferation of peroxisomes [3]. Subsequently, two other family members were discovered, PPARβ/δ and PPARγ [4, 5]. Natural ligands for the PPARs include native and modified polyunsaturated fatty acids and eicosanoids [6–8]. Additionally, the PPARs have a large ligand-binding pocket that can accommodate a diverse range of synthetic ligands [9–11].

All PPARs have four main domains named A/B, C, D, and E/F. The N-terminal A/B domain has a transcriptional activating function (AF-1). The C domain, or DNA binding domain (DBD), is formed by two zinc finger-like motifs that can recognize a peroxisome proliferator response element (PPRE) on target genes. PPREs are specific DNA sequences of the repetition of a consensus hexanucleotide sequence (AGGTCA), separated by one or two nucleotides. The D domain is a hinge region that can modulate the DNA binding ability and is involved in cofactor interaction. The E/F domain is the ligand-binding domain (LBD), which is responsible for the ligand binding and is involved in the dimerization with the 9-cis retinoic acid receptor (RXR) [12].

PPARs are expressed by several different immune cells, including macrophages [13–15], T cells [16–19], B cells [20], and dendritic cells [21–23]. Other than regulation of lipid metabolism, PPARs have also been shown to play an important role in regulating immune responses and inflammation, by programming inflammatory gene expression in immune cells, including macrophages, dendritic cells, and lymphocytes [8, 24, 25]. All three members of the PPAR
family have been shown to exert anti-inflammatory effects in vitro and in vivo. The anti-inflammatory effects of PPAR agonists have been observed in autoimmune diseases, including multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Although the detailed mechanisms by which PPARs regulate inflammatory responses and autoimmune encephalomyelitis are still not well established, recent studies have broadened our understanding on the transcriptional regulation of inflammatory target genes by PPARs and shed light on the mechanism of PPAR regulation of autoimmune encephalomyelitis. The positive regulation of target gene transcription by PPARs was through direct binding to the PPRE on the promoter of target genes, whereas negative regulation of target gene expression was mostly indirect, through a mechanism termed transrepression [6, 26]. This paper will summarize some general mechanisms by which PPARs regulate inflammatory gene expression and focus on the recent advances of PPAR regulation of autoimmune encephalomyelitis.

2. General Mechanisms of PPAR Action

2.1. Positive Regulation of Target Gene Expression. PPARs can both positively and negatively regulate their target gene expression. One of the mechanisms by which PPARs exert their function is through binding to a PPRE as a heterodimer with RXR in a ligand-dependent manner. Ligand-dependent activation is linked to the recruitment of coactivator complexes that modify chromatin structure and facilitate assembly of the general transcriptional machinery at the promoter [27, 28].

In the unliganded state, PPARs are associated with a nuclear receptor corepressor. NCoR (nuclear receptor corepressor) is among the most studied corepressors. In addition, heat shock protein-90 and the hepatitis virus B X-associated protein 2 have been shown to be associated with PPAR-α, which negatively regulates subsequent gene activation [29, 30]. Upon ligand activation, the PPARs undergo a conformational change that results in the dissociation from the corepressor, enabling the PPARs to bind nuclear receptor coactivators. These coactivators then act to reorganize the chromatin templates allowing the basal transcription machinery to gain access to the promoter regions and drive the transcription of target genes [24]. One example of positive regulation of inflammatory gene expression in autoimmune encephalomyelitis is the regulation of IL-4 gene by the PPARα agonist gemfibrozil. Gemfibrozil induced immune deviation and protected mice from EAE. PPAR-α was shown to regulate the IL-4 and IL-5 genes and bind to the IL-4 promoter in the presence of steroid receptor coactivator-1 (SRC-1), suggesting transactivation of the IL-4 gene [31].

2.2. Negative Regulation of Target Gene Expression by Transrepression. The ligand-dependent gene expression by PPARs is mediated through an indirect regulatory mechanism, termed ligand-dependent transrepression, which is distinguished from active repression of target genes in that the repression does not depend on the binding of PPARs to PPREs in target gene promoters. The general mechanism of transrepression involves protein-protein interactions between PPARs and their target transcription factors or coregulatory complexes. Transrepression is widely used to negatively regulate gene expression but the detailed mechanism by which different nuclear receptors exert their specific transrepression varies from receptor to receptor. It is difficult to identify a unified mechanism of repression by all PPARs, since signal, cell, and/or promoter-specific mechanisms exist for all three PPAR family members.

2.2.1. Tether Transcription Factors Away from Their Binding Sites. One of the mechanisms by which PPARs transrepress their target inflammatory gene expression is to tether transcription factors away from their DNA binding sites in the target gene promoter region, which in turn inhibits gene transcription of the target inflammatory genes. This process involves physical interaction between PPARs and their target transcription factors. The inhibition of phorbol ester-induced IL-2 expression by PPARγ was mediated by this mechanism. PPARγ ligands, troglitazone and 15 deoxy Delta (12, 14) prostaglandin J (2) (15d-PGJ2), inhibited IL-2 production and phthyoethylgullutinin-inducible proliferation in human peripheral blood T cells in a dose-dependent manner. The activated PPARγ physically associates with the transcription factor, nuclear factor of activated T cells (NFAT), regulating the IL-2 promoter by blocking NFAT DNA binding and transcriptional activity. The ligand-dependent binding of PPARγ to NFAT correlates with the dissociation of NFAT from the IL-2 promoter [32].

2.2.2. SUMOylation-Dependent Pathway. Another important transrepression pathway is the SUMOylation-dependent pathway. SUMOylation-dependent targeting of a nuclear receptor to corepressor complexes to prevent their signal-dependent clearance is likely to represent a general molecular strategy for transrepression of proinflammatory target genes [33, 34]. The SUMOylation-dependent pathway mediated transrepression of inflammatory response genes was first identified for PPARγ and then extended to PPARα and two additional members of the nuclear receptor family, LXRα and LXRβ. In macrophages, the SUMOylation-dependent pathway was initiated by ligand-induced SUMOylation of the PPARγ ligand-binding domain. This modified PPARγ in turn bound to NCoR complexes associated with the promoters of target inflammatory genes, which were marked by the presence of NCoR-HDAC3-TBL corepressor complexes. These complexes prevented Ubc5 recruitment in response to lipopolysaccharide (LPS) signals, which supposedly led to the clearance of NCoR and HDAC3, and the switch from repression to transcriptional activation. As a result, NCoR complexes were not cleared from the promoter, and target genes were maintained in a repressed state [33].

Collectively, recent studies have defined some molecular mechanisms by which PPARs positively or negatively regulate their target inflammatory gene expression. However, the molecular mechanisms by which PPARs regulate autoimmune encephalomyelitis have not been well defined. So far,
no study has been published demonstrating the detailed molecular mechanism of negative regulation of PPAR in the EAE model although Gocke et al. showed the molecular pathway of positive regulation of IL4 and IL5 gene by PPAR-α in EAE. More studies are needed in the future to elucidate the detailed mechanisms by which PPARs regulate autoimmune encephalomyelitis.

3. MS and EAE

MS is the leading cause of neurologic disability in the United States in young adults after trauma; thus, most patients suffer from the effects of MS for most of their adult life. MS is thought to be a T cell-mediated autoimmune disease of the central nervous system (CNS) with a complex genetic background. Although the precise etiology of MS is still unknown, it is generally accepted that MS begins with the formation of acute inflammatory lesions which are mediated by autoreactive T cells and B cells. The demyelinating plaques are dominated by activated T cells and macrophages associated with oligodendrocyte and myelin destruction (Figure 1).

CD4 T cells are at the center of MS pathogenesis and are the focus of MS research, given their important role in mediating disease. CD4 T cells differentiate into different types of T effector cells in the periphery in response to different pathogenic microorganisms as a result of recognition of these organisms by the innate immune system. It has been suggested for more than two decades that there are two different types of CD4 T helper cells, Th1 and Th2 cells. The Th1 cell subset mainly produces IFN-γ, IL-2 and GM-CSF, while the Th2 cell subset produces IL-4, IL-5 and IL-13 [35–38]. Th1 cells have been implicated in a variety of autoimmune diseases, including MS [39–41]. Conversely, Th2 cells control infections by extracellular microbes, and cytokines produced by Th2 cells mediate helper T cell functions for antibody production and mediate the immunopathology of allergic responses. Early studies suggested that the IFN-γ producing Th1 CD4 T cells, which were driven by IL-12, played an essential role in mediating disease, while Th2 cytokines such as IL-4 were associated with amelioration of EAE and remission in MS. More recently, Th17 cells have been identified as a new CD4 T cell lineage. In vivo, Th17 cells were driven by IL-23 although, in vitro, they were induced by TGF-β and IL-6. Th17 cells also have been shown to be critical in the development of autoimmune diseases. Studies have been done to define the roles of different T cell subpopulations in MS pathogenesis and focus on how to manipulate pathogenic Th1 and Th17 cells and related cytokines to suppress disease.

EAE is an inflammatory demyelinating disease mediated by myelin-specific Th1 and Th17 CD4 lymphocytes. EAE is characterized by relapsing paralysis, CNS inflammation, and demyelination. It has been used as a model for MS for several decades, since it shares clinical and immunopathological similarities to MS. EAE can be induced in mice by immunization with various myelin proteins or peptides emulsified in CFA or by the transfer of activated myelin-specific CD4 Th1 lymphocytes into naive recipients.

The anti-inflammatory properties of PPAR agonists have led to the investigation of PPAR functions in regulating autoimmune encephalomyelitis, hoping to develop new therapeutic strategies for MS. Many studies have been performed to test the effects of different PPAR agonists in regulating EAE and have shown very promising results. Some of the targets of PPARs in MS pathogenesis are shown in Figure 1. Based on these promising animal data, a PPAR agonist has been tested in a clinical trial as an adjunctive treatment for MS patients. In the next three sections, we are going to discuss the regulation of autoimmune encephalomyelitis by PPARγ, PPARα, and PPARβ/δ, respectively.

4. Regulation of Autoimmune Encephalomyelitis by PPARγ

4.1. PPARγ Agonists Suppress EAE. Several PPAR-γ agonists have been shown to ameliorate EAE. Troglitazone was shown to ameliorate MOG 35-55-induced EAE in C57BL/6 mice, and troglitazone treatment during the effector phase is more effective than when it is given during the induction phase [42]. Administration of another PPARγ agonist, 15d-PGJ2, before and at the onset of clinical signs of EAE significantly reduced the severity of disease in B10 PL mice. More importantly, culture of encephalitogenic T cells with 15d-PGJ2 reduced their ability to adoptively transfer EAE, suggesting that PPAR-γ ligands may regulate T cell encephalitogenicity in vitro [43]. Furthermore, the combination of 15d-PGJ2 and 9-cis-retinoic acid (RA), the ligand for RXR, resulted in enhanced amelioration of disease, suggesting that combination of RXR-specific ligands and PPARγ ligands may be highly effective in the treatment of autoimmune demyelinating diseases such as MS [44]. Similarly, in SJL/J mice, 15d-PGJ2 or Ciglitazone decreased the duration and clinical severity of active immunization and adoptive transfer models of EAE [45]. Orally administered pioglitazone was also shown to reduce the incidence and severity of monophasic, chronic disease in C57BL/6 mice and of relapsing disease in B10.PL mice. Pioglitazone also reduced clinical signs when it was provided after disease onset. The suppression of clinical signs was paralleled by decreased lymphocyte infiltration, lessened demyelination, reduced chemokine and cytokine expression, and increased inhibitor of κB (IκB) expression in the brain [46]. Another PPARγ agonist, rosiglitazone, when used to treat DCs, was able to prevent EAE development in mice [47].

On the other hand, PPARγ antagonists exacerbated EAE. Treatment with PPARγ antagonists, Bisphenol A diglycidyl ether (BADGE), or 2-Chloro-5-nitro-N-(4-pyridyl)benzamide (T0070907) increased the severity and duration of EAE in C57BL/6 wild-type and PPARγ-deficient mice. The exacerbation of EAE was associated with an augmented neural antigen-induced T cell proliferation, IFNγ production, and Th1 differentiation [48]. Furthermore, BADGE and benzamide (T0070907) reversed the inhibition of EAE by the PPARγ agonists, Ciglitazone and 15d-PGJ2, in C57BL/6 wild-type and PPARγ−/− mice. The reversal of EAE was associated with restoration of neural antigen-induced T cell proliferation, IFNγ production, and Th1
4.2 EAE in PPARγ-Deficient Mice. It is controversial whether PPARγ agonists such as 15d-PGJ2 require PPARγ for their anti-inflammatory function, because there are studies showing PPARγ-independent mechanisms in the induction of anti-inflammatory effects by 15d-PGJ2 [50]. PPARγ-deficient heterozygous mice were used to demonstrate the function of endogenous PPARγ in EAE. In the endogenous state, the PPARs are likely occupied by their fatty acid ligands, which may be produced at sites of inflammation. PPARγ-deficient heterozygous mice developed an exacerbated course of EAE with prolonged clinical signs compared to wild-type littermates. The exacerbation was associated with an increased expansion of CD4 and CD8 T cells and expression of CD40 and MHC class II molecules in response to antigen, confirming PPARγ as a critical regulator of EAE and perhaps MS [51].

4.3 Role of PPARγ in Regulating Immune Cells in EAE. Since studies in vivo showed PPARγ agonists inhibited CNS inflammation and demyelination in EAE, studies were done to elucidate the potential therapeutic mechanisms. Troglitazone has been shown to attenuate the inflammation and decreased the clinical signs through the attenuation of proinflammatory cytokine gene expression in the spinal cord [42]. In addition to this, additional studies have been published to show the different effects of PPARγ agonists on immune cells and CNS resident cells in EAE as described below.

4.3.1 Antigen-Presenting Cells. PPARγ agonists were shown to regulate the function of antigen-presenting cells, including monocyte/macrophages and dendritic cells. 15d-PGJ2 was shown to inhibit phorbol ester-induced nitric oxide (NO), TNF-α, IL-1, and IL-6 production by cells of the
monocyte/macrophage lineage, in part by antagonizing the activities of transcription factors such as AP-1 and NF-kB [14, 15]. Another PPARγ agonist, rosiglitazone, was shown to interfere with NF-kB activation in murine DCs. As a result, treated DCs showed impaired maturation and a reduced capacity to activate antigen-specific T cells and were able to prevent EAE development in mice [47].

4.3.2. T Cells. Since MS and EAE are suspected T cell-mediated autoimmune diseases, studies have been conducted to determine how PPARs regulate T cell function. 15d-PGJ2 was shown to inhibit the proliferation of Ag-specific T cells from myelin basic protein Ac1-11 TCR-transgenic mice and suppress IFN-γ, IL-10, and IL-4 production by lymphocytes. Similarly, the disease induction with 15d-PGJ2 or Ciglitazone in SJL/J mice was associated with a decrease in IL-12 production and differentiation of neural antigen-specific Th1 cells. Treatment of activated T cells with PPARγ agonists in vitro inhibited IL-12-induced activation of the JAK-STAT signaling pathway and Th1 differentiation [45]. Orally administered pioglitazone was also shown to reduce the antigen-dependent IFN-γ production from EAE-derived T cells [46].

In addition to pathogenic Th1 cells, Th17 cells have also been shown to be pathogenic in MS and EAE. One recent study identified PPARγ as a key negative regulator of human and mouse Th17 differentiation. PPARγ activation in CD4 T cells selectively suppressed Th17 differentiation through inhibition of TGF-β/IL-6 induced RORγt expression, but not differentiation into Th1, Th2, or regulatory T cells. More importantly, human CD4 T cells from healthy controls and MS patients were strongly susceptible to PPARγ-mediated suppression of Th17 differentiation, suggesting that PPARγ is a promising molecular target for specific immunointervention in Th17-mediated autoimmune diseases such as MS [52].

4.4. Role of PPARγ in CNS-Resident Cells in EAE. Other than regulating immune responses, PPARγ agonists were also shown to regulate the functions of CNS-resident cells, including microglia and astrocytes. It has been shown that PPARγ agonists modulate EAE, at least in part, by inhibiting the activation and cytokine production of microglia and astrocytes. 15d-PGJ2 together with 9-cis retinoic acid potently inhibited microglial cell activation and inhibit EAE development in mice [53]. Three TZDs, rosiglitazone, pioglitazone, cigitazone, and 15d-PGJ2, were all effective in inhibiting production of NO, the proinflammatory cytokines TNF-α, IL-1β, and IL-6, and the chemokine MCP-1 from microglia and astrocytes [54, 55]. 15d-PGJ2 and rosiglitazone inhibited the induction of IL-12p40, IL-12p70 (p35/p40), IL-23 (p19/p40), and IL-27p28 proteins by LPS-stimulated primary microglia. 15d-PGJ2 potently suppressed IL-12p40, IL-23, and IL-27p28 production by primary astrocytes, whereas rosiglitazone suppressed IL-23 and IL-27p28, but not IL-12p40 in these cells [56]. These effects on CNS-resident cells might contribute to the suppression of EAE by PPARγ agonists.

4.5. PPARγ Agonists and MS. PPARγ agonist pioglitazone was tested as an add-on therapy with interferon-β in a small cohort of relapsing remitting MS (RRMS) patients. RRMS patients taking IFNβ-1a were randomized to treatment with pioglitazone (30 mg daily, p.o.) or placebo and monitored clinically by EDSS and by MRI for 1 year. After 1 year, there were no significant differences in clinical signs as assessed by EDSS; however, MRI showed a significant reduction in gray matter atrophy and a trend for reduced lesion burden in the treatment group. These data suggested some beneficial effects for RRMS patients, and further trials need to be performed to establish clinical efficacy [57].

PPARγ involvement in autoimmune encephalomyelitis was also implicated by a population-based study in MS patients. The Ala allele of the PPARγ Pro12Ala polymorphism was strongly associated with delayed disease onset (44.1 ± 5.3 years versus 34.5 ± 4.2 years; P = .006). This study demonstrated that the Pro12Ala polymorphism resulting in an amino acid exchange in the N-terminal sequence of PPARγ may influence the onset of MS [58].

In summary, data from EAE studies showed that PPARγ agonists were able to suppress disease severity by regulating the functions of both immune cells and CNS-resident cells (Table 1), supporting PPARγ agonists as an effective treatment of autoimmune demyelinating diseases such as MS. Small-scale clinical data further confirmed that the PPARγ agonist pioglitazone maybe beneficial for RRMS patients. More clinical studies are needed to further establish clinical efficacy.

5. Regulation of Autoimmune Encephalomyelitis by PPARα

PPARα is expressed in different immune cells, including monocytes/macrophages, T cells, and B cells and plays an important role in regulating inflammation and cytokine production. PPARα agonists have also been tested in the treatment of EAE and shown to be protective [24]. However, recent studies showed, other than sharing the common anti-inflammatory effects of all three PPAR subtypes, PPARα had specific effects in inducing immune deviation in EAE. This specific regulation of immune deviation made these PPARα agonists very attractive candidates to be used therapeutically in treating Th1-mediated autoimmune diseases, including MS, in addition to their excellent track history as oral agents used to treat hypertriglyceridemia. Here we are going to focus on several recent studies demonstrating PPARα regulation of immune deviation, gender differences, and its role in CNS-resident cells (Table 2).

5.1. Immune Deviation Induced by PPARα Agonists

5.1.1. Immune Deviation. Th1 and Th2 cells are two distinct CD4 T cell lineages, and they play different roles in autoimmune diseases, including MS and EAE. Autoimmune diseases can be divided into those mediated by Th1 cells with primarily inflammatory manifestations and those mediated by Th2 cells whose manifestations are secondary to
autoantibody containing immune complexes [66]. Immune deviation was a term used to characterize an immune response where Th2 cells predominate, and one approach to the immunotherapy of inflammatory autoimmune disease, including MS, was the antigen-specific deviation of an immune response dominated by a Th1 response to a Th2 response.

Table 1: The effects of PPARγ agonists in EAE.

| Agonists (concentration) | Effects on immune cells | Effects on CNS cells | References |
|--------------------------|-------------------------|----------------------|------------|
| 15d-PGJ2 (100 ug/kg/day to 1 mg/kg/day) | Suppresses T cell proliferation | Inhibits CD40 expression on microglial cells. | Diab et al. [43, 44], Natarajan and Bright [45], Drew et al. [53], Storer et al. [54, 55], Xu and Drew [56] |
| Pioglitazone (5–10 mg/kg/day) | Reduces T-cell activation. Suppresses Th17 differentiation in CD4 cells. | Inhibits production of NO, TNF-α, IL-1β, and IL-6, and MCP-1 from microglia and astrocytes. | Feinstein et al. [46], Klotz et al. [52], Drew et al. [53], Storer et al. [54, 55] |
| Rosiglitazone (5–10 mg/kg/day) | Inhibits NF-Kb Activation in DC. | Inhibits production of NO, TNF-α, IL-1β, and IL-6, and MCP-1 from microglia and astrocytes. | Iruretagoyena et al. [47], Feinstein et al. [46], Drew et al. [53], Storer et al. [54, 55], Xu and Drew [56] |
| Ciglitazone (50–100 ug/kg/day) | Inhibit IL-12 production in macrophages and Th1 differentiation. | Inhibit IL-12 production in microglial cells. | Natarajan and Bright [45], Drew et al. [53], Storer et al. [54, 55] |
| Troglitazone (50–100 mg/kg/day) | Suppresses TNF-α expression in spinal cord. | | Niino et al. [42] |

5.1.2. PPARα Agonists Ameliorate EAE by Inducing Immune Deviation. The PPARα agonist gemfibrozil was shown to regulate immune responses by promoting the deviation of immune responses dominated by a pathogenic Th1 response to a nonpathogenic Th2 response [31, 60, 67]. Lovett-Racke et al. demonstrated that PPARα agonists induced a shift in cytokine production from Th1 cytokines to Th2 cytokines in both mouse and human T cells and protected mice from EAE. PPARα agonists increased the production of the Th2 cytokine, IL-4, and suppressed proliferation by TCR transgenic T cells specific for the myelin basic protein Ac1-11 peptide. Oral administration of PPARα agonists gemfibrozil and fenofibrate inhibited the clinical signs of EAE. More importantly, the PPARα agonist gemfibrozil shifted the cytokine secretion of human T cell lines from IFNγ secretion to IL-4 secretion [59]. Gocke et al. studied the molecular mechanisms by which PPARα agonists induce immune deviation and protect mice from EAE. They demonstrated that PPARα agonists directly activated Th2 cytokine IL-4 gene expression by directly binding to the IL-4 promoter region. Gemfibrozil treatment increased Th2 transcription factor GATA-3 expression and decreased Th1 transcription factor T-bet expression in vitro and directly ex vivo. For the first time, they showed that PPARα regulated the IL-4 and IL-5 genes and bound the IL-4 promoter in the presence of the steroid receptor coactivator-1 [31].

5.1.3. Is the Effect Receptor Dependent or Not? Gocke et al. showed that the protective effects of PPARα agonists in EAE occurred in a receptor-dependent manner [31]. Dasgupta et al. observed similar effects with the PPARα agonist Gemfibrozil in mice, including switching of a Th1 profile to a Th2 profile, inhibiting T-bet expression, stimulating GATA3 expression, and inhibiting the encephalitogenicity of antigen-primed T cells. However, they suggested the switch of immune response from a Th1 to a Th2 profile by PPARα agonists was receptor independent, as the drug was equally effective in treating EAE in PPARα-deficient and well as wild-type mice [60]. Similarly, Cunard et al. showed that treatment with WY14,643 and other fibrates led to marked increases in supernatant concentrations of IL-4. They also showed that this effect on IL4 production was largely through
Table 2: The effects of PPARα agonists in EAE.

| Agonists (concentration) | Effects on immune cells | Effects on CNS cells | References |
|--------------------------|-------------------------|----------------------|------------|
| Gemfibrozil (500 ug/day)  | Suppress lymphocyte proliferation. Increase IL4 production in T cells. Inhibit IFNγ production. Inhibit the encephalitogenicity of MBP-primed T cells. Switch the immune response from a Th1 to a Th2 profile. Increase GATA-3 expression and decrease T-bet expression. Regulate the IL-4 and IL-5 genes. | Reduce NO production by microglia. Inhibit IL-1β and IL-6 production by astrocytes. | Lovett-Racke [59], Dasgupta et al. [60], Gocke et al. [31] |
| Fenofibrate              | Suppress lymphocyte proliferation | Inhibit NO production by microglial cells and astrocytes. Inhibit TNF-α expression, IL-1β and IL-6 production by astrocytes. Inhibit NF-κB binding activity in astrocytes. Repress IL-12p40, IL-12p70, IL-23 and IL-27p28 production by microglia. | Lovett-Racke [59], Xu et al. [61, 62] |
| Ciprofibrate             | Suppress lymphocyte proliferation. Increase IL4 production in T cells. | Inhibit IL-1β and IL-6 production by astrocytes | Lovett-Racke [59], Xu et al. [62] |
| WY 14643                 | Increase IL4 production in splenocytes | Inhibit NO production by astrocytes. Inhibit TNF-α expression, IL-1β and IL-6 production by astrocytes. | Xu et al. [62], Cunard et al. [18, 19] |

PPARα-agonists regulate CNS-resident cells in EAE. Moreover, PPARα agonists were also shown to regulate CNS-resident cells and the protective effects of PPARα agonists in EAE were in part through effects on CNS cells. Microglia cells are resident CNS cells that may serve as antigen-presenting cells. Activated microglia exhibit increased pathogenic cytokine production and increased synthesis of NO, which may contribute to axonal degradation in MS. Xu et al. showed that PPARα agonists inhibited microglia production of NO, IL-1β, and TNF-α, which were potentially toxic to cells including myelin-producing oligodendrocytes.

Women are more susceptible than men to develop autoimmune diseases, including MS. In MS, twice as many women as men develop the disease. This may be related to the fact that women have more robust immune responses than men although the exact mechanism is not understood [68]. A study showed women to be more prone than men to develop Th1-polarized responses directed against myelin antigens during MS [69]. Whether PPARα is responsible for the gender differences in MS susceptibility remains to be determined.

5.3. PPARα Regulation of CNS-Resident Cells in EAE. Moreover, PPARα agonists were also shown to regulate CNS-resident cells and the protective effects of PPARα agonists in EAE were in part through effects on CNS cells. Microglia cells are resident CNS cells that may serve as antigen-presenting cells. Activated microglia exhibit increased pathogenic cytokine production and increased synthesis of NO, which may contribute to axonal degradation in MS. Xu et al. showed that PPARα agonists inhibited microglia production of NO, IL-1β, and TNF-α, which were potentially toxic to cells including myelin-producing oligodendrocytes. In
addition, these agonists inhibit microglial production of Th1- and Th17-promoting cytokines, IL-12 and IL-23 [61]. PPARα agonists also suppressed microglia production of MCP-1, a chemokine that plays an important role in modulating monocyte infiltration into the CNS in MS [70]. Similar effects were observed in LPS-stimulated astrocytes. A combination of 9-cis RA and the PPARα agonist fenofibrate or gemfibrozil cooperatively inhibited NO, TNF-α, IL-1β, IL-6, and MCP-1 production by these cells [62]. Thus, PPARα agonists could also modify cytokine expression in the CNS during inflammation such as that observed in EAE or MS.

6. Regulation of Autoimmune Encephalomyelitis by PPARβ/δ

PPARβ/δ is the predominant PPAR isotype in brain. However, the exact functions of PPARβ/δ are not yet well understood, but it is likely to play a role in cell proliferation [71], differentiation, survival, lipid metabolism, and development [72, 73].

6.1. PPAR-β/δ-Specific Agonists and EAE. A protective effect in EAE was reported for a PPAR-β/δ-specific agonist, and this protection was suggested to be due to a reduction in glial inflammation. Polak et al. showed that oral administration of the selective PPARδ agonist GW0742 reduced clinical signs in actively immunized C57BL/6 mice, especially when it was administered during disease progression [63]. The protective effect of GW0742 was receptor dependent, since no amelioration of EAE clinical scores was observed in PPARδ-deficient mice [64]. RT-PCR analysis showed that GW0742 increased expression of some myelin genes. GW0742 reduced astroglial and microglial inflammatory activation and IL-1β levels in EAE brain.

Other than GW0742, two other PPARβ/δ agonists, GW501516 and L165041, were shown to ameliorate MOGp35-55-induced EAE in C57BL/6 mice by blocking IFN-γ and IL-17 production by Th1 and Th17 cells [65]. GW 501516 was also tested for its capacity to protect from antibody-mediated demyelination. However, GW 501516 did not protect against antibody-mediated demyelination although it showed some anti-inflammatory activity [74].

The regulation of EAE by PPARβ was further confirmed by a study in Steroid receptor coactivator-3-(SRC-3) deficient mice. SRC-3 is a member of the p160 family of coactivators that interact with nuclear receptors to enhance their transactivation in a ligand-dependent manner. SRC-3 deficiency significantly inhibited the disease severity of EAE. However, these effects are not caused by inhibition of peripheral T cell response, but by upregulation of PPARβ in the CNS, which induced an alternative activation state of microglia in SRC-3 deficient mice. These alternatively activated microglia inhibited CNS inflammation through inhibition of proinflammatory cytokines and chemokines, such as TNF-α, IFN-γ, CCL2, CCL3, CCL5, and CXCL10 as well as upregulation of the anti-inflammatory cytokine IL-10 and opsonins [75].

6.2. PPARβ/δ Regulation of Immune Responses. Treatment of T-cells with GW0742 either in vivo or in vitro did not reduce Th1 cytokine IFNγ production [63]. However, a study showed that the PPARδ agonists, GW501516 and L165041, ameliorated EAE by blocking IFNγ and IL-17 production by Th1 cells and Th17 cells and was associated with a decrease in IL-12 and IL-23 and an increase in IL-4 and IL-10 expression in the CNS and lymphoid organs [65].

The PPARβ/δ regulation of immune cells was further confirmed by one recent study in PPARβ/δ-deficient mice. PPARβ/δ-deficient mice developed a severe inflammatory

| Agonists (concentration) | Effects on immune cells | Effects on CNS cells | References |
|--------------------------|--------------------------|----------------------|------------|
| GW0742 (10 mg/kg/day)    | Inhibit the expression of IFN-γ, IL-17, T-bet, IL-12 and IL-23. | Increase the number of myelin-producing OLs. Increase noggin protein expression in both OPCs and enriched astrocyte cultures. | Polak et al. [63], Simonini et al. [64] |
| GW501516 (25–100 ug/day) | Inhibit the expression of IFN-γ, IL-17, T-bet, IL-12 and IL-23. | Increase the expression of IL-4 and IL-10. | Kanakasabai et al. [65] |
| L165041 (25–100 ug/day)  | Inhibit the expression of IFN-γ, IL-17, T-bet, IL-12 and IL-23. | Increase the expression of IL-4 and IL-10. | Kanakasabai et al. [65] |
response during EAE characterized by a striking accumulation of IFN-γ+ IL17A- and IFN-γ+ IL17A+ CD4+ cells in the spinal cord, which resulted from immune system aberrations including enhanced Th cell expansion, cytokine production, and T-bet expression and enhanced expression of IL-12 family cytokines by myeloid cells. This data strongly suggests that PPAR-δ serves as an important molecular brake for the control of autoimmune inflammation [76] (Table 3).

6.3. PPARβ/δ and Oligodendrocyte (OL) Maturation. The special feature of PPARδ function is that PPARδ agonists are more effective when administered during later stages of disease and they increase myelin gene expression [63], which suggested that they might affect OL maturation. Vittoria Simonini et al. demonstrated that PPARδ played a role in OPC maturation. GW0742 was shown to increase the number of myelin-producing OLs in OPCs, and this was receptor dependent, since OLs were reduced in PPAR-deficient OPCs [64].

7. Conclusion

PPARs are lipid-activated transcription factors that have emerged as key regulators of both lipid metabolism and inflammation. They exert positive and negative controls over the expression of a range of inflammatory genes. The anti-inflammatory properties of PPARs make them attractive targets for intervention in human autoimmune diseases, including MS. A growing body of literature suggested that PPAR agonists could be used therapeutically in autoimmune diseases such as MS as a preliminary clinical study has suggested. Further studies will be required to fully understand the complicated mechanisms of PPAR regulation of immune responses and autoimmune encephalomyelitis.

References

[1] L. Mukundan, J. I. Odegard, C. R. Morel et al., “PPAR-α senses and orchestrates clearance of apoptotic cells to promote tolerance,” Nature Medicine, vol. 15, no. 11, pp. 1266–1272, 2009.
[2] I. Szatmari and L. Nagy, “Nuclear receptor signalling in dendritic cells connects lipids, the genome and immune function,” EMBO Journal, vol. 27, no. 18, pp. 2353–2362, 2008.
[3] I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
[4] S. A. Kiefer, B. M. Forman, B. Blumberg et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994.
[5] P. Tontonoz, E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman, “mPPARγ2: tissue-specific regulator of an adipocyte enhancer,” Genes and Development, vol. 8, no. 10, pp. 1224–1234, 1994.
[6] C. Hong and P. Tontonoz, “Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors,” Current Opinion in Genetics and Development, vol. 18, no. 5, pp. 461–467, 2008.
[7] M. V. Chakravarthy, I. J. Lodhi, L. Yin et al., “Identification of a Physiologically Relevant Endogenous Ligand for PPARα in Liver,” Cell, vol. 138, no. 3, pp. 476–488, 2009.
[8] S. J. Bensinger and P. Tontonoz, “Integration of metabolism and inflammation by lipid-activated nuclear receptors,” Nature, vol. 454, no. 7205, pp. 470–477, 2008.
[9] R. T. Gampe Jr., V. G. Montana, M. H. Lambert et al., “Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors,” Molecular Cell, vol. 5, no. 3, pp. 545–555, 2000.
[10] I. T. Itoh, L. Fairall, K. Amin et al., “Structural basis for the activation of PPARγ by oxidized fatty acids,” Nature Structural and Molecular Biology, vol. 15, no. 9, pp. 924–931, 2008.
[11] C. D. Kane, K. A. Stevens, J. E. Fischer et al., “Molecular characterization of novel and selective peroxisome proliferator-activated receptor α agonists with robust hypolipidemic activity in vivo,” Molecular Pharmacology, vol. 75, no. 2, pp. 296–306, 2009.
[12] C. Diradourian, J. Girard, and J.-P. Pégrier, “Phosphorylation functions and oligomerization of PPARγ: modulation by inflammatory stimuli,” Molecular Pharmacology, vol. 75, no. 2, pp. 33–40, 2005.
[13] G. Chinetti, S. Griglio, M. Antonucci et al., “Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998.
[14] C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998.
[15] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.
[16] D. C. Jones, X. Ding, and R. A. Daynes, “Nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is expressed in resting murine lymphocytes. The PPARα in T and B lymphocytes is both transactivation and transcription competent,” Journal of Biological Chemistry, vol. 277, no. 9, pp. 6838–6845, 2002.
[17] D. C. Jones, B. M. Manning, and R. A. Daynes, “A role for the peroxisome proliferator-activated receptor α in T-cell physiology and ageing immunobiology,” Proceedings of the Nutrition Society, vol. 61, no. 3, pp. 363–369, 2002.
[18] R. Cunard, D. DiCampli, D. C. Archer et al., “WY14,643, a PPARα ligand, has profound effects on immune responses in vivo,” Journal of Immunology, vol. 169, no. 12, pp. 6806–6812, 2002.
[19] R. Cunard, M. Ricote, D. DiCampli et al., “Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors,” Journal of Immunology, vol. 168, no. 6, pp. 2795–2802, 2002.
[20] K. Setoguchi, Y. Misaki, Y. Terachi et al., “Peroxisome proliferator-activated receptor-γ haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis,” Journal of Clinical Investigation, vol. 108, no. 11, pp. 1667–1675, 2001.
[21] P. Gosset, A.-S. Charbonnier, P. Delerive et al., “Peroxisome proliferator-activated receptor-γ activators affect the maturation of human monocyte-derived dendritic cells,” European Journal of Immunology, vol. 31, no. 10, pp. 2857–2865, 2001.
[22] C. Faveeuw, S. Fouqueray, V. Angeli et al., “Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells,” FEBS Letters, vol. 486, no. 3, pp. 261–266, 2000.
[23] I. Szatmari, P. Gogolak, J. S. Im, B. Dezsö, E. Rajnavolgyi, and L. Nagy, "Activation of PPARy specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion," *Immunity*, vol. 21, no. 1, pp. 95–106, 2004.

[24] Y. Yang, A. R. Gocke, A. Lovett-Racke, P. D. Drew, and M. K. Racke, "PPAR alpha regulation of the immune response and autoimmune encephalomyelitis," *PPAR Research*, Article ID 546753, 2008.

[25] C. K. Glass and S. Ogawa, "Combinatorial roles of nuclear receptors in inflammation and immunity," *Nature Reviews Immunology*, vol. 6, no. 1, pp. 44–55, 2006.

[26] J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, "From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions," *Progress in Lipid Research*, vol. 45, no. 2, pp. 120–159, 2006.

[27] C. K. Glass and M. G. Rosenfeld, "The coregulator exchange in transcriptional functions of nuclear receptors," *Genes and Development*, vol. 14, no. 2, pp. 121–141, 2000.

[28] N. J. McKenna and B. W. O’Malley, "Combinatorial control of gene expression by nuclear receptors and coregulators," *Cell*, vol. 108, no. 4, pp. 465–474, 2002.

[29] W. K. Sumanasekera, E. S. Tien, J. W. Davis II, R. Turpey, G. H. Perdew, and J. P. V. Heuvel, "Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-α (PPARα) and PPARβ activity," *Biochemistry*, vol. 42, no. 36, pp. 10726–10735, 2003.

[30] W. K. Sumanasekera, E. S. Tien, R. Turpey, J. P. Vanden Heuvel, and G. H. Perdew, "Evidence that peroxisome proliferator-activated receptor α is complexed with the 90-kDa heat shock protein and the hepatitis virus B X-associated protein 2," *Journal of Biological Chemistry*, vol. 278, no. 7, pp. 4467–4473, 2003.

[31] A. R. Gocke, R. Z. Hussain, Y. Yang et al., "Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-alpha agonists in autoimmune disease," *Journal of Immunology*, vol. 182, no. 7, pp. 4479–4487, 2009.

[32] X. Y. Yang, L. H. Wang, T. Chen et al., "Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT," *Journal of Biological Chemistry*, vol. 275, no. 7, pp. 4541–4544, 2000.

[33] G. Pascual, A. L. Fong, S. Ogawa et al., "A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ," *Nature*, vol. 437, no. 7059, pp. 759–763, 2005.

[34] S. Ghisletti, W. Huang, S. Ogawa et al., "Parallel SUMOylation-dependent pathways mediate gene-and signal-specific transrepression by LXRαs and PPARγ," *Molecular Cell*, vol. 25, no. 1, pp. 57–70, 2007.

[35] T. R. Mosmann and R. L. Coffman, "TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties," *Annual Review of Immunology*, vol. 7, pp. 145–173, 1989.

[36] M. Rocken, J.-H. Saurat, and C. Hauser, "A common precursor for CD4+ T cells producing IL-2 or IL-4," *Journal of Immunology*, vol. 148, no. 4, pp. 1031–1036, 1992.

[37] Y. Kamogawa, L.-A. E. Minasi, S. R. Carding, K. Bottomly, and R. A. Flavell, "The relationship of IL-4 and IFNγ-producing T cells studied by lineage ablation of IL-4-producing cells," *Cell*, vol. 75, no. 5, pp. 985–995, 1993.

[38] A. K. Abbas, K. M. Murphy, and A. Sher, "Functional diversity of helper T lymphocytes," *Nature*, vol. 383, no. 6603, pp. 787–793, 1996.

[39] U. Christen and M. G. von Herrath, "Manipulating the type 1 vs type 2 balance in type 1 diabetes," *Immunologic Research*, vol. 30, no. 3, pp. 309–325, 2004.

[40] M. K. Gately, L. M. Renzetti, J. Magram et al., "The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses," *Annual Review of Immunology*, vol. 16, pp. 495–521, 1998.

[41] S. Trembleau, T. Germann, M. K. Gately, and L. Adorini, "The role of IL-12 in the induction of organ-specific autoimmune diseases," *Immunology Today*, vol. 16, no. 8, pp. 383–386, 1995.

[42] M. Niino, K. Iwabuchi, S. Kikuchi et al., "Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-γ," *Journal of Neuroimmunology*, vol. 116, no. 1, pp. 40–48, 2001.

[43] A. Diab, C. Deng, J. D. Smith et al., "Peroxisome proliferator-activated receptor-γ agonist 15-deoxy-D12,14-prostaglandin J2 ameliorates experimental autoimmune encephalomyelitis," *Journal of Immunology*, vol. 168, no. 5, pp. 2508–2515, 2002.

[44] A. Diab, R. Z. Hussain, A. E. Lovett-Racke, J. A. Chavis, P. D. Drew, and M. K. Racke, "Ligands for the peroxisome proliferator-activated receptor-γ and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis," *Journal of Neuroimmunology*, vol. 148, no. 1-2, pp. 116–126, 2004.

[45] C. Natarajan and J. J. Bright, "Peroxisome proliferator-activated receptor-gamma agonist inhibit experimental allergenic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation," *Genes and Immunity*, vol. 3, no. 2, pp. 59–70, 2002.

[46] D. L. Feinstein, E. Galea, V. Gavrilyuk et al., "Peroxisome proliferator-activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis," *Annals of Neurology*, vol. 51, no. 6, pp. 694–702, 2002.

[47] M. I. Iruretagoyena, S. E. Sepúlveda, J. P. Lezana et al., "Inhibition of nuclear factor-κB enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis," *Journal of Pharmacology and Experimental Therapeutics*, vol. 318, no. 1, pp. 59–67, 2006.

[48] H. P. Raikwar, G. Muthian, J. Rajasighing, C. Johnson, and J. J. Bright, "PPARγ antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis," *Journal of Neuroimmunology*, vol. 167, no. 1-2, pp. 99–107, 2005.

[49] H. P. Raikwar, G. Muthian, J. Rajasighing, C. N. Johnson, and J. J. Bright, "PPARγ antagonists reverse the inhibition of neural antigen-specific Th1 response and experimental allergic encephalomyelitis by Ciglitazone and 15-Deoxy-Δ12,14-Prostaglandin J2," *Journal of Neuroimmunology*, vol. 178, no. 1, pp. 76–86, 2006.

[50] A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans, "PPARγ-dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation," *Nature Medicine*, vol. 7, no. 1, pp. 48–52, 2001.

[51] J. J. Bright, C. Natarajan, G. Muthian, Y. Barak, and R. M. Evans, "Peroxisome proliferator-activated receptor-γ-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis," *Journal of Neuroimmunology*, vol. 171, no. 11, pp. 5743–5750, 2003.
[52] L. Klutz, S. Burgdorf, I. Dani et al., “The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity,” The Journal of experimental medicine, vol. 206, no. 10, pp. 2079–2089, 2009.

[53] P. D. Drew, P. D. Storer, J. Xu, and J. A. Chavis, “Hormone regulation of microglial cell activation: relevance to multiple sclerosis,” Brain Research Reviews, vol. 48, no. 2, pp. 322–327, 2005.

[54] P. D. Storer, J. Xu, J. Chavis, and P. D. Drew, “Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis,” Journal of Neuroimmunology, vol. 161, no. 1-2, pp. 113–122, 2005.

[55] P. D. Storer, J. Xu, J. A. Chavis, and P. D. Drew, “Cyclopentenone prostaglandins PGA2 and 15-deoxy-Δ 12,14 PGJ2 suppress activation of marine microglia and astrocytes: implications for multiple sclerosis,” Journal of Neuroscience Research, vol. 80, no. 1, pp. 66–74, 2005.

[56] J. Xu and P. D. Drew, “Peroxisome proliferator-activated receptor-γ agonists suppress the production of IL-12 family cytokines by activated glia,” Journal of Immunology, vol. 178, no. 3, pp. 1904–1913, 2002.

[57] C. C. Kaiser, D. K. Shukla, G. T. Stebbins et al., “A pilot test of cytokine expression in the CNS: relevance to multiple sclerosis,” Journal of Neuroimmunology, vol. 72, no. 4, pp. 934–946, 2007.

[58] A. E. Lovett-Racke, R. Z. Hussain, S. Northrop et al., “Peroxisome proliferator-activated receptor α agonists as therapy for autoimmune disease,” Journal of Immunology, vol. 172, no. 9, pp. 5790–5798, 2004.

[59] S. Dasgupta, A. Roy, M. Jana, D. M. Hartley, and K. Pahan, “Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-α,” Molecular Pharmacology, vol. 72, no. 4, pp. 934–946, 2007.

[60] J. Xu, M. K. Racke, and P. D. Drew, “Peroxisome proliferator-activated receptor-α agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis,” Journal of Neurochemistry, vol. 103, no. 5, pp. 1801–1810, 2007.

[61] J. Xu, J. A. Chavis, M. K. Racke, and P. D. Drew, “Peroxisome proliferator-activated receptor-α and retinoid X receptor agonists inhibit inflammatory responses of astrocytes,” Journal of Neuroimmunology, vol. 176, no. 1-2, pp. 95–105, 2006.

[62] P. E. Polak, S. Kalinin, C. Dello Russo et al., “Protective effects of a peroxisome proliferator-activated receptor-β/δ agonist in experimental autoimmune encephalomyelitis,” Journal of Neuroimmunology, vol. 168, no. 1-2, pp. 65–75, 2005.

[63] M. V. Simonini, P. E. Polak, A. I. Boulléne, J. M. Peters, J. C. Richardson, and D. L. Feinstein, “Regulation of oligodendrocyte progenitor cell maturation by PPAR: effects on bone morphogenetic proteins,” ASN Neuro, vol. 2, no. 1, Article ID e00025, pp. 1–13, 2010.

[64] S. Kanakasabai, W. Chearwae, C. C. Walline, W. Iams, S. M. Adams, and J. J. Bright, “Peroxisome proliferator-activated receptor δ agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis,” Immunology, vol. 130, no. 4, pp. 572–588, 2010.

[65] M. Goldman, P. Druet, and E. Gleichmann, “TH2 cells in systemic autoimmunity: insights from allogeneic diseases and chemically-induced autoimmunity,” Immunology Today, vol. 12, no. 7, pp. 223–227, 1991.

[66] S. E. Dunn, S. S. Ousman, R. A. Sobel et al., “Peroxisome proliferator-activated receptor (PPARα) expression in T cells mediates gender differences in development of T cell-mediated autoimmunity,” Journal of Experimental Medicine, vol. 204, no. 2, pp. 321–330, 2007.

[67] C. C. Whitacre, S. C. Reingold, and P. A. O’Looney, “A gender gap in autoimmunity,” Science, vol. 283, no. 5406, pp. 1277–1278, 1999.

[68] C. M. Pelfrey, A. C. Cotleur, J.-C. Lee, and R. A. Rudick, “Sex differences in cytokine responses to myelin peptides in multiple sclerosis,” Journal of Neuroimmunology, vol. 130, no. 1-2, pp. 211–223, 2002.

[69] J. Xu, P. D. Storer, J. A. Chavis, M. K. Racke, and P. D. Drew, “Agonists for the peroxisome proliferator-activated receptor-α and the retinoid X receptor inhibit inflammatory responses of microglia,” Journal of Neuroscience Research, vol. 81, no. 3, pp. 403–411, 2005.

[70] D. J. Kim, I. A. Murray, A. M. Burns, F. J. Gonzalez, G. H. Perdew, and J. M. Peters, “Peroxisome proliferator-activated receptor-β/δ inhibits epidermal cell proliferation by down-regulation of kinase activity,” Journal of Biological Chemistry, vol. 280, no. 10, pp. 9519–9527, 2005.

[71] L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptors β/δ: emerging roles for a previously neglected third family member,” Current Opinion in Lipidology, vol. 14, no. 2, pp. 129–135, 2003.

[72] M. G. Hall, L. Quignodon, and B. Desvergne, “Peroxisome proliferator-activated receptor β/δ in the brain: facts and hypothesis,” PPAR Research, Article ID 780452, 2008.

[73] A. Defauw, M.-G. Zurich, O. Braissant, P. Honegger, and F. Monnet-Tschudi, “Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination,” Journal of Neuroinflammation, vol. 6, article no. 15, 2009.

[74] Y. Xiao, J. Xu, S. Wang et al., “Genetic ablation of steroid receptor coactivator-3 promotes PPAR-β/δ-mediated alternative activation of microglia in experimental autoimmune encephalomyelitis,” GLIA, vol. 58, no. 8, pp. 932–942, 2010.

[75] S. E. Dunn, R. Bhat, D. S. Straus et al., “Peroxisome proliferator-activated receptor δ limits the expansion of pathogenic Th cells during central nervous system autoimmunity,” Journal of Experimental Medicine, vol. 207, no. 8, pp. 1599–1608, 2010.